ADAM SKY: Open Payments
NPI 1346388667 · CREVE COEUR, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$130,869 in 285 payments from 16 companies in 2025. Trend: 2023 $197,349 · 2024 $218,592 · 2025 $130,869
Speaker / faculty: $110,152Travel & lodging: $15,342Food & beverage: $4,704Consulting: $560Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 108 | $87,423 |
| Otsuka America Pharmaceutical, Inc. | 83 | $41,907 |
| Vanda Pharmaceuticals Inc. | 15 | $244 |
| ABBVIE INC. | 14 | $241 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $219 |
| Lundbeck LLC | 15 | $217 |
| E.R. Squibb & Sons, L.L.C. | 15 | $194 |
| Lilly USA, LLC | 5 | $97 |
| Axsome Therapeutics, Inc. | 4 | $69 |
| Neurocrine BioSciences, Inc. | 3 | $65 |
Products named: AUSTEDO XR, REXULTI, UZEDY, FANAPT, VRAYLAR, CAPLYTA, COBENFY, KISUNLA.
Industry payments across MO — which companies pay providers there.
